In vitro bone metastasis dwelling in a 3D bioengineered niche.


Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 08 2020
revised: 06 12 2020
accepted: 18 12 2020
pubmed: 10 1 2021
medline: 25 5 2021
entrez: 9 1 2021
Statut: ppublish

Résumé

Bone is the most frequent metastasis site for breast cancer. As well as dramatically increasing disease burden, bone metastases are also an indicator of poor prognosis. One of the main challenges in investigating bone metastasis in breast cancer is engineering in vitro models that replicate the features of in vivo bone environments. Such in vitro models ideally enable the biology of the metastatic cells to mimic their in vivo behavior as closely as possible. Here, taking benefit of cutting-edge technologies both in microfabrication and cancer cell biology, we have developed an in vitro breast cancer bone-metastasis model. To do so we first 3D printed a bone scaffold that reproduces the trabecular architecture and that can be conditioned with osteoblast-like cells, a collagen matrix, and mineralized calcium. We thus demonstrated that this device offers an adequate soil to seed primary breast cancer bone metastatic cells. In particular, patient-derived xenografts being considered as a better approach than cell lines to achieve clinically relevant results, we demonstrate the ability of this biomimetic bone niche model to host patient-derived xenografted metastatic breast cancer cells. These patient-derived xenograft cells show a long-term survival in the bone model and maintain their cycling propensity, and exhibit the same modulated drug response as in vivo. This experimental system enables access to the idiosyncratic features of the bone microenvironment and cancer bone metastasis, which has implications for drug testing.

Identifiants

pubmed: 33421710
pii: S0142-9612(20)30871-1
doi: 10.1016/j.biomaterials.2020.120624
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120624

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Weijing Han (W)

Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France; Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France.

Rania El Botty (R)

Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France.

Elodie Montaudon (E)

Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France.

Laurent Malaquin (L)

LAAS-CNRS, Université de Toulouse, CNRS, F-31400, Toulouse, France.

Frederic Deschaseaux (F)

STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France.

Nicolas Espagnolle (N)

STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France.

Elisabetta Marangoni (E)

Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France.

Paul Cottu (P)

Department of Medical Oncology, Institut Curie and Paris Sciences et Lettres Research University, 75005, Paris, France.

Gérard Zalcman (G)

Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France; Thoracic Oncology Department and Early Phase Unit CIC-1425, Hôpital Bichat, AP-HP, Université de Paris, 75018, Paris, France.

Maria Carla Parrini (MC)

Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France.

Franck Assayag (F)

Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France.

Luc Sensebe (L)

STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France.

Pascal Silberzan (P)

Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France.

Anne Vincent-Salomon (A)

Department of Pathology, Institut Curie Hospital, 26, Rue D'Ulm, F-75248, Paris, France.

Guillaume Dutertre (G)

Surgical Oncology Department, Institut Curie, PSL Research University, 75005, Paris, France.

Sergio Roman-Roman (S)

Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France.

Stephanie Descroix (S)

Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France. Electronic address: Stephanie.descroix@curie.fr.

Jacques Camonis (J)

Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France. Electronic address: jacques.camonis@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH